Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl

NCT05006118 PHASE1 COMPLETED

This is an open-label study to evaluate the PK and excretion of a single oral dose of \[14C\]-rodatristat ethyl. The study will consist of: Screening evaluations (within 29 days prior to dosing); a treatment phase (from dosing until discharge from the unit, a minimum of 7 days and a maximum of 14 days); and discharge procedures.

Details

Lead sponsor	Altavant Sciences GmbH
Phase	PHASE1
Status	COMPLETED
Enrolment	5
Start date	Thu Sep 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy

Interventions

• Radio-labeled rodatristat ethyl 600 mg

Countries

United States